Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push

On August 6, Teleflex Incorporated (NYSE: TFX ) reported second-quarter results for the period ended June 30, and the numbers told two different stories at once. Revenue from continuing operations climbed to $570.3 million, up 28.9% from a year earlier, while GAAP diluted earnings per share slid to $0.96 from $1.54. Add in a completed divestiture, a fresh share buyback, and a trimmed full-year outlook, and you have a company mid-transformation asking shareholders for patience.

Teleflex's core businesses did the heavy lifting. Vascular revenue rose 9.0% to $246.3 million, and Surgical grew 9.1% to $112.1 million, both ahead of the roughly 8% and 9% currency-adjusted growth rates reported for those units. Adjusted diluted earnings per share ticked up to $1.76 from $1.73, a smaller gain than the topline growth but a gain nonetheless.

The bigger story is what management did with the balance sheet. Teleflex closed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, generating an estimated $1.25 billion after tax, and used part of that to pay off its $700 million Term Loan A-2. The company also bought back $250 million of stock in the quarter at an average price of $130.85 per share, leaving $750 million available under its buyback authorization, and it plans another $250 million accelerated repurchase starting August 7, 2026. That capital return is part of why full-year adjusted diluted earnings per share guidance moved up to $6.90 to $7.20.

On the innovation side, Teleflex won FDA approval in late July for EZPLAZ, the first freeze-dried plasma licensed in the United States, and advanced its Freesolve resorbable scaffold program, with four-year data from the BIOMAG-I study showing durable long-term performance, enrollment finished ahead of schedule in BIOMAG-II, and the first patient procedures completed in the U.S. BIOMAG-III trial in June.

That earnings growth looks thinner once you separate the pieces. GAAP diluted earnings per share fell to $0.96 from $1.54 a year earlier. Management also cut its outlook across the board, lowering full-year GAAP revenue growth guidance to a range of 13.40% to 14.40%, GAAP earnings per share guidance to $2.54 to $2.84, and pro forma adjusted constant currency revenue growth guidance to 3.50% to 4.50%.

The reason traces back to the Biotronik Vascular Intervention business Teleflex acquired last year. Integration is progressing, but taking longer than expected, and it shows up in the numbers: Interventional revenue on a pro forma adjusted constant currency basis actually fell 1.0% in the quarter even as reported Interventional revenue jumped 86.1% on the strength of the acquisition itself. Cash on hand also declined, ending the quarter at $316.9 million versus $402.7 million at the end of 2025, and Teleflex added $500 million of new senior notes carrying a 5.875% coupon, well above the 4.625% notes they replaced.